Cardiovascular disease: much more aggressive in patients with type 2 diabetes.

被引:25
|
作者
Chiquette E. [1 ]
Chilton R. [1 ]
机构
[1] University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, 78284-7872, TX
关键词
Coronary Artery Bypass Graft; Pravastatin; United Kingdom Prospective Diabetes Study; Left Internal Mammary Artery; Silent Ischemia;
D O I
10.1007/s11883-002-0037-z
中图分类号
学科分类号
摘要
It is estimated that 80% of individuals with type 2 diabetes die of coronary heart disease. Several factors have been found to contribute to the accelerated atherosclerosis present in diabetic patients. These include hyperglycemia-induced endothelial cell dysfunction, impaired fibrinolysis, increased platelet aggregation, and dysfunctional arterial remodeling. The evidence supports that a healthy lifestyle, statin drugs, angiotensin-converting enzyme inhibitors, and aspirin can modify these factors and slow the atherosclerosis process observed in type 2 diabetes. Because of the high prevalence of cardiovascular disease in people with type 2 diabetes, early cardiac testing is indicated. The optimal strategy for coronary revascularization in diabetic patients remains controversial and is discussed in detail in this review.
引用
收藏
页码:134 / 142
页数:8
相关论文
共 50 条
  • [41] Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
    Mancia, Giuseppe
    Grassi, Guido
    DIABETOLOGIA, 2018, 61 (03) : 517 - 525
  • [42] Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
    Giuseppe Mancia
    Guido Grassi
    Diabetologia, 2018, 61 : 517 - 525
  • [43] Type 2 Diabetes: How Much of an Autoimmune Disease?
    de Candia, Paola
    Prattichizzo, Francesco
    Garavelli, Silvia
    De Rosa, Veronica
    Galgani, Mario
    Di Rella, Francesca
    Spagnuolo, Maria Immacolata
    Colamatteo, Alessandra
    Fusco, Clorinda
    Micillo, Teresa
    Bruzzaniti, Sara
    Ceriello, Antonio
    Puca, Annibale A.
    Matarese, Giuseppe
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [44] Subclinical thyroid disease in Type 2 diabetes. Is it worth to screen?
    Raposo, JF
    Pratas, S
    Fernandes, C
    Valadas, C
    Duarte, R
    Gardete-Correia, L
    Boavida, J
    DIABETOLOGIA, 2004, 47 : A329 - A330
  • [45] Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes.
    Solomon, Scott D.
    Uno, Hajime
    Lewis, Eldrin F.
    Eckardt, Kai-Uwe
    Lin, Julie
    Burdmann, Emmanuel A.
    de Zeeuw, Dick
    Ivanovich, Peter
    Levey, Andrew S.
    Parfrey, Patrick
    Remuzzi, Giuseppe
    Singh, Ajay K.
    Toto, Robert
    Huang, Fannie
    Rossert, Jerome
    McMurray, John J. V.
    Pfeffer, Marc A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1146 - 1155
  • [46] Prevention of cardiovascular disease: Much more is needed
    De Backer, Guy G.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2018, 25 (10) : 1083 - 1086
  • [47] Glycemic Control Achieved with Insulin Glargine Analyzed by Cardiovascular Risk Factors in Patients with Type 2 Diabetes.
    Blonde, L.
    Baron, M.
    Zhou, R.
    Banerji, M. A.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [48] Achievement of cardiovascular goals in patients diagnosed with type 2 diabetes with and without cardiovascular disease
    Garzon, Gerardo
    Gil, Angel
    Maria Herrero, Ana
    Jimenez, Fernando
    Jose Cerezo, Maria
    Dominguez, Cristina
    GACETA SANITARIA, 2015, 29 (06) : 425 - 430
  • [49] β-KLOTHO IN PATIENTS WITH TYPE 1 DIABETES.
    Iniguez, German
    Gaete, Ximena
    Miranda, Lia
    Lopez, Patricia
    Mira, Magdalena
    Codner, Ethel
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 606 - 606
  • [50] Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
    Maryam Khavandi
    Francisco Duarte
    Henry N. Ginsberg
    Gissette Reyes-Soffer
    Current Cardiology Reports, 2017, 19